Repligen (NASDAQ:RGEN) Price Target Raised to $208.00 at HC Wainwright

Repligen (NASDAQ:RGEN) had its price objective upped by HC Wainwright from $180.00 to $208.00 in a research report sent to investors on Monday,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

Other research analysts also recently issued reports about the stock. Weiss Ratings downgraded shares of Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, March 3rd. KeyCorp reaffirmed an “overweight” rating on shares of Repligen in a report on Wednesday, February 25th. Wells Fargo & Company decreased their target price on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. UBS Group lowered their price target on shares of Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Wednesday, February 25th. Finally, Wall Street Zen lowered shares of Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $176.92.

Repligen Price Performance

RGEN opened at $116.35 on Monday. The company has a current ratio of 8.37, a quick ratio of 7.12 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $6.55 billion, a P/E ratio of 136.88, a PEG ratio of 2.23 and a beta of 1.15. The stock has a 50-day moving average price of $139.18 and a 200-day moving average price of $146.88. Repligen has a 12-month low of $102.96 and a 12-month high of $175.77.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The company had revenue of $197.91 million for the quarter, compared to analysts’ expectations of $192.23 million. Repligen had a return on equity of 4.71% and a net margin of 6.62%.Repligen’s revenue for the quarter was up 18.1% compared to the same quarter last year. During the same period last year, the firm posted $0.44 EPS. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Equities analysts predict that Repligen will post 1.72 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Repligen

Several institutional investors and hedge funds have recently bought and sold shares of RGEN. Price T Rowe Associates Inc. MD lifted its stake in Repligen by 31.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock worth $753,603,000 after acquiring an additional 1,091,683 shares during the period. United Capital Financial Advisors LLC purchased a new position in Repligen during the 3rd quarter valued at $368,387,000. Opti Capital Management LP purchased a new position in Repligen during the 4th quarter valued at $2,399,209,000. Holocene Advisors LP raised its holdings in Repligen by 47.0% in the 3rd quarter. Holocene Advisors LP now owns 1,377,104 shares of the biotechnology company’s stock worth $184,077,000 after purchasing an additional 440,290 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in Repligen by 43.9% in the 4th quarter. Invesco Ltd. now owns 1,256,439 shares of the biotechnology company’s stock worth $205,880,000 after purchasing an additional 383,399 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.